Clinical trial · Interventional
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer
NCT00003256CI-TRIAL-00009409completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| alvocidib | Drug | Alvocidib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
- interventionNames
- Drug: alvocidib
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
PATIENT CHARACTERISTICS: * Performance Status: ECOG 0-2 * Life Expectancy: At least 3 months * WBC at least 3,000/mm3 * Absolute neutrophil count at least 1,200/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 8 g/dL * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2.5 times normal * Creatinine no greater than 1.5 mg/dL * Prostate-specific antigen at least 10 ng/mL (if bone only disease) * No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer * No serious medical illness * No cord compression symptoms PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No prior suramin therapy * Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other concurrent hormonal therapy) * No prior anti-androgen therapy within 4 weeks of study * At least 4 weeks since prior radiotherapy * No prior strontium therapy
References
Publications (1)
- RESULTLiu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 1;10(3):924-8. doi: 10.1158/1078-0432.ccr-03-0050. PMID 14871968